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Anti-CD3 antibody therapy is used to treat transplant
rejection and has been applied in several autoimmune
diseases, such as type I diabetes and ulcerative colitis,
but its potential in HAM/TSP has not been investigated.
Therefore, we explored the effect of ex vivo treatment
(24-96h) of PBMCs from HAM/TSP patients (n=15)
and healthy controls (n=20, all from Salvador-Bahia,
Brazil) with an anti-CD3 monoclonal antibody approved
for in vivo treatment post-transplantation (produced
under GMP conditions). In contrast to normal donors
and patients in early disease stages, anti-CD3 treatment
did not increase lymphoproliferation in PBMCs from
advanced HAM/TSP patients (EDSS>4), but strongly
induced apoptosis. In addition, anti-CD3 treatment did
not induce a pro-inflammatory cytokine storm, either at
the protein or mRNA level. Therefore, anti-CD3 treat-
ment ex vivo might eliminate pathogenic T cells
through activation-induced cell death. Since we have
previously shown that pro-apoptotic capacity decreases
over time in HAM/TSP patients, both defective (Fas-
mediated) apoptosis and excessive lymphoproliferation,
more pronounced in patients with advanced disease pro-
gression, can be restored by anti-CD3 treatment. Using
microarray analysis, we found that treatment of HAM/
TSP PBMCs with anti-CD3 mAb had a pronounced
effect on gene expression, significantly (p<0.001) down-
regulating 1918 genes (including pro-inflammatory
genes) and up-regulating 1926 genes, including cell
cycle-related and immunoregulatory genes, such as
CTLA4. In conclusion, our results suggest anti-CD3
monoclonal antibody might be a possible therapeutic
alternative in HAM/TSP, due to its immunomodulatory
effect, by inducing apoptosis, reducing exacerbated lym-
phoproliferation and stimulating anti-inflammatory gene
expression and/or proliferation of cells with immunore-
gulatory capacity.
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